BioCentury | Aug 8, 2019
Distillery Techniques

Nanoparticle-based system for nucleic acid therapy delivery and monitoring of disease progression in thoracic aortic dissection

...therapy to the thoracic aortic dissection. In a mouse model of the disease, delivery of microRNA-145 (miR-145)...
...Beijing University of Chemical Technology, Beijing, China email: xufj@mail.buct.edu.cn Claire Quang Beijing University of Chemical Technology Capital Medical University MicroRNA-145 (miR-145) Cardiovascular...
BioCentury | Jul 17, 2018
Distillery Therapeutics

Cancer

...INDICATION: Breast cancer; lung cancer Patient sample and mouse studies suggest miR-130a and miR-145 or their...
...In tumor samples from patients with breast or lung cancers, low levels of miR-130a and miR-145...
...splenic myeloid cells from two orthotopic mouse models of breast cancer, levels of miR-130a and miR-145...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: microRNA-145 (miR-145)

...with an anti-miR-145 antisense oligonucleotide accumulated in the lung and several other tissues, and decreased miR-145...
...an RNA-based therapeutic formulated with the nanoparticles, in preclinical testing to treat PAH. TARGET/MARKER/PATHWAY: microRNA-145 (miR-145)...
BioCentury | Jun 25, 2015
Translation in Brief

Celsion's silent approach

...using it to deliver an antisense oligonucleotide targeting microRNA-145 (miR-145) in a rat model of PAH. miR-145...
...the pulmonary vasculature in PAH patients. In the rats, TheraSilence nanoparticles loaded with anti-miR-145 decreased miR-145...
...were published online last month in the Journal of Controlled Release .But Celsion isn't pursuing miR-145...
BioCentury | Jul 1, 2013
Clinical News

Egen preclinical data

...In a rat model of PAH, IV administration of a microRNA-145 inhibitor using Egen's Staramine-mPEG delivery...
BioCentury | Apr 18, 2013
Distillery Therapeutics

Indication: Cancer

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Head and neck cancer ADAM17; microRNA-145 (miR-145)...
...SRY (sex determining region Y)-box 9 (SOX9); IL-6 Mouse and cell culture studies suggest increasing miR-145...
...squamous cell carcinomas. In mice grafted with head and neck cancer-derived tumor-initiating cells, overexpression of miR-145...
BioCentury | Mar 11, 2013
Company News

miRagen, University of Glasgow deal

...The university granted miRagen exclusive rights to IP covering microRNA-145 . The IP was discovered under...
...U.K.) to develop the target to treat pulmonary arterial hypertension (PAH). The partners have studied microRNA-145...
BioCentury | Jan 13, 2011
Distillery Therapeutics

Indication: Cancer

...cancer MicroRNA-143 (miR-143); miR-145 Studies in mice and in zebrafish suggest that increasing miR-143 and miR-145...
...help treat Ras-driven cancers. In mice and zebrafish with K-Ras mutant pancreatic cancers, miR-143 and miR-145...
...expressing wild-type K-Ras. In mice with human pancreatic cancer cells, vector expression of miR-143 and miR-145...
BioCentury | Oct 26, 2009
Clinical News

Geniom Real Time Analyzer: Postmarketing study data

...down-regulated in patients with relapsing-remitting MS (RRMS) vs. healthy controls. The most significantly deregulated biomarker, has-miR-145...
BioCentury | May 14, 2009
Distillery Techniques

Technology: Drug platforms

...This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms MicroRNA-145 to...
Items per page:
1 - 10 of 10